Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 2/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26673160 | 1.00 | PLA2G1B (0.47) | PLA2G1BPLA2G2ADNM1TSHRTHRB | |
| SCHEMBL9785896 | 0.98 | PLA2G1B (0.43) | PLA2G1BPLA2G2ADNM1TSHRTHRB | |
| SCHEMBL8938916 | 0.98 | PLA2G1B (0.43) | PLA2G1BPLA2G2ADNM1TSHRTHRB | |
| SCHEMBL23228807 | 0.93 | PLA2G1B (0.41) | PLA2G1BPLA2G2ADNM1OPRM1KDM5A | |
| SCHEMBL30929603 | 0.91 | PLA2G1B (0.52) | PLA2G1BPLA2G2ADNM1TSHRTHRB | |
| SCHEMBL9245364 | 0.91 | PLA2G1B (0.52) | PLA2G1BPLA2G2ADNM1TSHRTHRB | |
| SCHEMBL11756994 | 0.91 | PLA2G1B (0.52) | PLA2G1BPLA2G2ADNM1TSHRTHRB | |
| SCHEMBL9252490 | 0.91 | PLA2G1B (0.52) | PLA2G1BPLA2G2ADNM1TSHRTHRB | |
| SCHEMBL11785881 | 0.91 | PLA2G1B (0.52) | PLA2G1BPLA2G2ADNM1TSHRTHRB | |
| SCHEMBL20445604 | 0.90 | PLA2G1B (0.40) | PLA2G1BPLA2G2ADNM1OPRM1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902985-B2 | Chemoenzymatic methods for synthesizing moenomycin analogs | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-02-27 | — | — | US | disclosed |
| US-9428438-B2 | Process for preparing formic acid | BASF SE (DE) | 2016-08-30 | — | — | US | disclosed |
| EP-2925715-A1 | METHOD FOR PRODUCING FORMIC ACID | BASF SE (DE) | 2015-10-07 | — | — | EP | disclosed |
| EP-2794539-B1 | METHOD FOR PRODUCING FORMIC ACID | BASF SE (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-20150119561-A1 | CHEMOENZYMATIC METHODS FOR SYNTHESIZING MOENOMYCIN ANALOGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-30 | — | — | US | disclosed |
| US-20150079618-A1 | METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-03-19 | — | — | US | disclosed |
| US-8889905-B2 | Process for preparing formic acid | BASF SE (DE) | 2014-11-18 | — | — | US | disclosed |
| EP-2794540-A1 | PROCESS FOR PREPARING FORMIC ACID | BASF SE (DE) | 2014-10-29 | — | — | EP | disclosed |
| EP-2794539-A1 | METHOD FOR PRODUCING FORMIC ACID | BASF SE (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8835683-B2 | Process for preparing formic acid | BASF SE (DE) | 2014-09-16 | — | — | US | disclosed |
| WO-2014082845-A1 | METHOD FOR PRODUCING FORMIC ACID | BASF SE (DE) | 2014-06-05 | — | — | WO | disclosed |
| US-20140148617-A1 | PROCESS FOR PREPARING FORMIC ACID | BASF SE (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20140018456-A1 | PROCESS FOR PREPARING FORMIC ACID | BASF SE (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20130190532-A1 | PROCESS FOR PREPARING FORMIC ACID | BASF SE (DE) | 2013-07-25 | — | — | US | disclosed |
| WO-2013092403-A1 | METHOD FOR PRODUCING FORMIC ACID | BASF SE (DE) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092157-A1 | PROCESS FOR PREPARING FORMIC ACID | BASF SE (DE) | 2013-06-27 | — | — | WO | disclosed |
| US-20110136759-A1 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-09 | — | — | US | disclosed |
| US-6576684-B1 | Ammonium, phosphonium or sulfonium containing oligomers or polymers; controlled molecular weight, low polydispersity and a vinyl or dienyl end group; polymeric precursors and addi-tives | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-10 | — | — | US | disclosed |
| EP-1112288-A1 | THERMAL- AND PHOTOINITIATED RADICAL POLYMERIZATION IN THE PRESENCE OF AN ADDITION FRAGMENTATION AGENT | Ciba SC Holding AG (CH) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000011041-A1 | THERMAL- AND PHOTOINITIATED RADICAL POLYMERIZATION IN THE PRESENCE OF AN ADDITION FRAGMENTATION AGENT | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119561-A1 | CHEMOENZYMATIC METHODS FOR SYNTHESIZING MOENOMYCIN ANALOGS | CYP51A1, COASY, MRM1 | PLA2G1B 2672/4885PLA2G2A 2926/4885DNM1 492/4885 |
| US-20140148617-A1 | PROCESS FOR PREPARING FORMIC ACID | MSMO1, FEN1, MED1 | PLA2G1B 533/4885PLA2G2A 551/4885DNM1 136/4885 |
| US-20140018456-A1 | PROCESS FOR PREPARING FORMIC ACID | F2, F5, FAH | PLA2G1B 3150/4885PLA2G2A 3291/4885DNM1 2185/4885 |
| US-20110136759-A1 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | MSN, MGAM, NISCH | PLA2G1B 2204/4885PLA2G2A 2090/4885DNM1 96/4885 |
| US-20130190532-A1 | PROCESS FOR PREPARING FORMIC ACID | F5, F12, ADH1A | PLA2G1B 1701/4885PLA2G2A 2118/4885DNM1 1212/4885 |
| US-20150079618-A1 | METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS | MAGT1, GALNT1, NMT1 | PLA2G1B 2602/4885PLA2G2A 2581/4885DNM1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.